Steroidogenic Pathways - GDX
3 β HSD 3 β HSD 17,20 Lyase 17,20 Lyase CYP2 1 17-hydroxylase 17-hydroxylase CYP2 1 CYP11b 1 5 α β 5 β 11βHSD 3 β HS D COMT COMT 17βHSD 3A 4 1 A 1 5 α 3 α HS D 17βHSD 1B1 17βHSD 5 β 5 α 17βHSD Aromatase (CYP19)
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
Bacteriology - Genova Diagnostics, Inc.
www.gdx.net© Genova Diagnostics · A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director · CLIA Lic. #34D0655571 · Medicare Lic. #34-8475 Patient: SAMPLE PATIENT
Bacteriology - Genova Diagnostics, Inc.
www.gdx.netBacteriology Mycology Lactobacillus species *NG Escherichia coli *NG Bifidobacterium *NG Klebsiella pneumoniae NP 3+ Geotrichum species PP 3+ *NG *NG NP PP P Human microflora is influenced by environmental factors and the competitive ecosystem of the organisms in the GI tract. Pathological significance should be based upon
Stool Testing Support Guide - GDX
www.gdx.netMICROBIOME ANALYSIS The GI Effects features a synthesis of the patient’s microbiome data. In addition to listing amounts of the 24 commensal bacteria, Genova has developed unique algorithms that account for the levels of bacteria and translate the patient’s microbiome data into clinically actionable information. The commensal microbiome
Interpretive Guide - GDX
www.gdx.net• Consider adding multi-strain probiotic 25 • For elevated beta-glucuronidase also consider calcium-d-glucarate26 • First treat abnormalities in the Infection, Inflammation, and & Insufficiency pillars • For potential pathogens, consider pharmaceutical or non-pharmaceutical (botanical) antibiotic and/or antifungal agents (based on
GI Effects 2200 Sample Report - Home | Genova Diagnostics
www.gdx.net'\velrvlv 3dwwhuqv bbbbb =rqh b bb7kh frpphqvdo suriloh lq wklv ]rqh grhv qrw doljq zlwk surilohv dvvrfldwhg zlwk lqwhvwlqdo lqiodppdwlrq ru lppxqrvxssuhvvlrq ,i lqiodppdwru\ elrpdunhuv duh suhvhqw rwkhu fdxvhv qhhg wr eh h[foxghg vxfk dv lqihfwlrq irrg doohuj\ ru pruh vhulrxv sdwkrorj\ =rqh b bb7klv sdwwhuq ri edfwhuld lv dvvrfldwhg
Results Overview - GDX
www.gdx.netLow B2 may result from chronic alcoholism, some anti-psychotic medications, oral contraceptives, tricyclic antidepressants, quinacrine or adriamycin. B2 deficiency may result in oxidative stress, mitochondrial dysfunction, low uric acid, low B3 or B6, high homocysteine, anemia or oral & throat inflammation.
Related documents
The Diagnosis and Management of Nonalcoholic Fatty Liver ...
aasldv2019stg.aasld.orgNonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases Naga Chalasani,1 Zobair Younossi ,2 Joel E. Lavine,3 Michael Charlton,4 Kenneth Cusi,5 Mary Rinella,6 Stephen A. Harrison,7 Elizabeth M. Brunt,8 and Arun J. Sanyal9 Preamble This guidance provides a data-supported approach to
Alcoholic Liver Disease: Introduction
www.hopkinsmedicine.org2) and may be macrovesicular (large droplets) or microvesicular (small droplets). Other conditions, such as nonalcoholic fatty liver disease, drug toxicity and fatty liver of pregnancy may cause steatosis that is indistinguishable from alcoholic fatty liver. Fatty liver is a completely reversible lesion, assuming the patient abstains from alcohol.
ELEVATED LIVER ENZYMES
web.brrh.comThe Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index (ANI) •ANI is novel scoring system that accurately distinguishes alcoholic liver disease (ALD) from nonalcoholic fatty liver disease (NAFLD) •Most accurate when MELD <20
Bariatric Surgery and Procedures
static.cigna.como evidence of fatty liver disease (i.e., nonalcoholic fatty liver disease [NAFLD] or nonalcoholic steatohepatitis [NASH]) o gastroesophageal reflux disease (GERD) refractory to medical therapy • A thorough multidisciplinary evaluation within the previous 12 months which includes ALL of …
一般社団法人 日本肝臓学会
www.jsh.or.jpnonalcoholic fatty liver disease (NAFLD) NAFLD nonalcoholic steatohepatitis (NASH) —-370. NASH titis Z. NASH 'NASH 60%, ONAFLD It, NAFLD 13-100 (apoB-100), VLDL (kwashiorkor E) VLDL D Z. NAFLD/NASH (first hit), (second hit) 0 two-hit theo- theory 1 . NAFLDD-Y½ NAFLD < , NAFLD N ASH NASH 10—20 (simple steatosis) n. NASH O NASH 21 NASH Z. ÐI.
Management of Hypertriglyceridemia: Common Questions …
www.aafp.orgJun 03, 2020 · Liver disease Nonalcoholic fatty liver disease ... toxic effects from free fatty acids released by pancreatic lipase.1,14,15 A cohort study found that triglyceride levels
Non-Alcoholic Fatty Liver Disease: A Patient’s Guide
www.hepatitis.va.govFatty liver (steatosis) occurs when the liver has more than 5 -10% of its weight in fat. NAFLD is related to obesity, diabetes and often abnormal levels of fat in the blood and high blood pressure. Fatty liver in isolation does not damage the liver, however nonalcoholic steatohepatitis (NASH) …
| American Association of Clinical Endocrinology
pro.aace.comfish (especially fatty fish); lean meat and skinless poultry; limit processed foods Start with low duration and intensity of activity and increase slowly until activity goals are met Screen for and treat sleep apnea Lifestyle modification Address substance abuse Refer to mental health professionals as needed Avoid passive exposure to tobacco smoke